USPTO serial 99457144
ENTRAYNIA
Reviewed by CopyMark Law Group
Status 730Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- SHINN, LAUREN DONGMI
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with ENTRAYNIA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $249*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jayme M. Torelli
Jayme M. Torelli Hoffman Warnick LLC6 Tower Pl1st FloorAlbany, NY 12203Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of fatigue; Pharmaceutical preparations for the treatment of narcolepsy; Pharmaceutical preparations for the treatment of levodopa-induced dyskinesias in Parkinson's Disease; Pharmaceutical preparations for the treatment of viral pneumonia; Pharmaceutical preparations for the treatment of social anxiety disorder and social anxiety disorder performance-only subtype; Pharmaceutical preparations for the treatment of respiratory distress, acute respiratory distress syndrome, and inflammatory lung injury; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations for the reduction of cravings for alcohol, food, nicotine, opioids, or opiates; Pharmaceutical preparations for facilitating emergence from general anesthesia; Pharmaceutical preparations for improving cognition; Pharmaceutical preparations for the treatment of gastric motility and gastric emptying disorders | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 26, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 25, 2026 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Mar 25, 2026 | EXT1 | SOU EXTENSION 1 FILED | — |
| Mar 25, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 10, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 13, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 13, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 7, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 15, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 10, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 22, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 22, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 22, 2025 | NWAP | NEW APPLICATION ENTERED | — |